Administration of the two-dose adjuvanted hepatitis B virus vaccine (Heplisav-B, Dynavax Technologies) may be cost-effective in many of the adults recommended for HBV vaccination by the CDC and may result in cost savings in some high-risk groups (Vaccine 2021;39[33]:4733-4741).
However, uptake of the two-dose vaccine may not be as high as it could be, according to Catherine Freeland, MPH, the public health program director of the Hepatitis B Foundation.
“I don’t think